&nbsp;

ICCU-Vaping-Poster_AODA-fr.pdf

New

May 2025

Document

Inuit-Depistage-du-cancer-du-sein.pdf

New

Jun 2025

Document

Inuit-Depistage-cancer-du-col-de-luterus.pdf

New

Jun 2025

Document

Inuit-Depistage-du-cancer-colorectal.pdf

New

Jun 2025

Document

Inuit-Depistage-cancer-du-poumon.pdf

New

Jun 2025

Regimen

ABIRNIRPPRED

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

Exceptional Access Program

niraparib / abiraterone - For the treatment of metastatic castration resistant prostate cancer in patients with a BRCA mutation

ODB - General Benefit

prednisone

Drugs Used:

niraparib / abiraterone,

prednisone

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

ATEZ

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Atezolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer

New Drug Funding Program

Atezolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer

Drugs Used:

atezolizumab,

atezolizumab (subcut)

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

ATEZ(MNT)

Cancer Type:

Lung,

Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer

New Drug Funding Program

Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer

Drugs Used:

atezolizumab,

atezolizumab (subcut)

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

ATEZ

Cancer Type:

Lung,

Non-Small Cell

Intent: Adjuvant

Funding:

New Drug Funding Program

Atezolizumab - Adjuvant Treatment for Non-Small Cell Lung Cancer

New Drug Funding Program

Atezolizumab - Adjuvant Treatment for Non-Small Cell Lung Cancer

Drugs Used:

atezolizumab,

atezolizumab (subcut)

Quick Link(s):

Regimen Monograph

Jun 2025

Document

Accompagnement-dans-votre-parcours-de-soins-palliatifs.pdf

New

Jun 2025

Drug

ipilimumab

Other Name(s): Yervoy®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Aug 2024

Regimen

IBRU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For relapsed and refractory Mantle Cell Lymphoma, according to clinical criteria

Drugs Used:

iBRUtinib